Sampling strategy to calculate the cyclosporin-A area under the time-concentration curve

American Journal of Transplantation

Volumn 2, Issue 6, 2002, Pages 546-550

  David Neto, Elias ^a   Araujo, Lilian M P ^a   Brito, Zita M L ^a   Alves, Cristiane F ^a   Lemos, Francine C ^a   Yagyu, Elisa M ^a   Nahas, William C ^a   Ianhez, Luiz E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

2 hour concentration; Abbreviated AUC; Area under the time concentration curve; C2; Cyclosporin A; Pharmacokinetics; Renal transplantation

Indexed keywords

CYCLOSPORIN A;

ADULT; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; DRUG STABILITY; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; REGRESSION ANALYSIS; SAMPLING; VALIDATION PROCESS;

EID: 0036664389     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2002.20609.x     Document Type: Article

References (20)

1. Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68: 55-62.
2. Belitsky P, Dunn S, Johnston A, Levy G. Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients. Clin Pharmacokinet 2000; 39: 117-125.
3. Schwartzman BS, Cavalcante JS, Yagyu EM et al. Impact of cyclosporin A pharmacokinetics on the presence of side effects in pediatric renal transplantation. J Am Soc Nephrol 2000; 11: 343-349.
4. Brito ZML, Alves CF, Paula FJ et al. A randomized, open-label, prospective study comparing two different cyclosporin a areas under the time-concentration curve for the prevention of rejection in renal transplantation (Abstract no. 221). Am J Transplantation 2001; 1: 191.
5. Shaw L, Holt DW, Yatscoff R et al. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit 1995; 17: 642-654.
6. Roy A, Murphy G, Tan A et al. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8). Transplantation 1999; 67: 1133-1137.
7. Cantarovich M, Besner JG, Barkun JS, Elstein E, Loertscher R. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant 1998; 12: 243-249.
8. Metrakos P, Alpert E, Deschenes M et al. Cyclosporine peak levels provide a better correlation with the area-under-the-curve than trough levels in liver transplant patients treated with neoral. Transplant Proc 1998; 30: 1462-1463.
9. Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999; 68: 1356-1361.
10. McMichael J, Burckart G, Shaw S et al. Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine+rapamycin regimen. Transplantation 2000; 69: 432-436.
11. Gaspari F, Anedda MF, Signorini O, Remuzzi G, Perico N. Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration. J Am Soc Nephrol 1997; 8: 647-652.
12. Gaspari F, Perico N, Signorini O, Caruso R, Remuzzi G. Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Technical note. Kidney Int 1998; 54: 2146-2150.
13. Marsh CL. Abbreviated pharmacokinetic profiles in area-under-the-curve monitoring of cyclosporine therapy in de novo renal transplant patients treated with Sandimmune or Neoral. Neoral study group. Ther Drug Monit 1999; 21: 27-34.
14. Meier-Kriesche HU, Kaplan B, Brannan P, Kahan BD, Portman RJ. A limited sampling strategy for the estimation of eight-hour neoral areas under the curve in renal transplantation. Ther Drug Monit 1998; 20: 401-407.
15. Kundt G, Hehl EM, Bast R et al. Comparison of several approaches of therapeutic drug monitoring of cyclosporin A based on individual pharmacokinetics. Eur J Clin Pharmacol 2000; 56: 43-48.
16. Swinford R, Kahan BD, Brannan P et al. A limited sampling strategy for the estimation of Neoral AUCs in pediatric patients. Pediatr Nephrol 1999; 13: 742-747.
17. Medeiros M, Perez-Urizar J, Munoz R, Castaneda-Hernandez G. Limited sampling model for area-under-the-curve monitoring in pediatric patients receiving either Sandimmune or Neoral cyclosporin A oral formulations. Pediatr Transplant 1999; 3: 225-230.
18. Dello Strologo L, Campagnano P, Federici G, Rizzoni G. Cyclosporine A monitoring in children, abbreviated area under curve formulas and C2 level. Pediatr Nephrol 1999; 13: 95-97.
19. Filler G, Mai I, Filler S, Ehrich JH. Abbreviated cyclosporine AUCs on Neoral - the search continues! Pediatr Nephrol 1999; 13: 98-102,
20. Farquhar JE, Nath CE, Knight JF et al. Pharmacokinetics of cyclosporin in children with stable renal transplants. Pediatr Nephrol 2000; 15: 167-170.